pharma · Multiple Myeloma · Ovarian Cancer · CASIF
CASI Pharmaceuticals drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 11 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
CASI Pharmaceuticals drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
US regulatory status: approved. Mechanism: Unknown.
Development asset linked to CASI Pharmaceuticals in public FDA and regional records.
US regulatory status: approved. Molecular target: Estrogen receptor.
Development asset linked to CASI Pharmaceuticals in public FDA and regional records.
US regulatory status: approved. Molecular target: Antithrombin-III.
Development asset linked to CASI Pharmaceuticals in public FDA and regional records.
US regulatory status: approved. Molecular target: DNA.
US regulatory status: approved. Molecular target: DNA.
Development asset linked to CASI Pharmaceuticals in public FDA and regional records.
Development asset linked to CASI Pharmaceuticals in public FDA and regional records.